

Contents

| | | |
|----------|--|-----------|
| 1 | General Principles of Animal Selection and Normal Physiological Values | 1 |
| | Special Requirement Considerations..... | 2 |
| | Normal Physiological Data | 3 |
| 2 | Preanesthesia, Anesthesia, Chemical Restraint, and the Recognition and Treatment of Pain and Distress | 17 |
| | General Principles of Pain Recognition in Animals..... | 17 |
| | The Use of Anti-Cholinergic Drugs for Preanesthesia..... | 21 |
| | General Comments on Preanesthetic Agents | 22 |
| | Preanesthesia and Anesthesia in Rats and Mice..... | 22 |
| | Chemical Restraint (Sedation) in Rats and Mice | 23 |
| | Pain and Distress Recognition in Rats and Mice | 23 |
| | Treatment of Pain in Rats and Mice | 26 |
| | Local Anesthetic Agents..... | 26 |
| | Nonsteroidal Anti-Inflammatory Drugs | 26 |
| | Narcotics..... | 26 |
| | Preanesthesia and Anesthesia in Rabbits..... | 28 |
| | Chemical Restraint (Sedation) in Rabbits | 29 |
| | Pain Recognition in Rabbits | 29 |
| | Treatment of Pain in Rabbits | 29 |
| | Local Anesthetics | 29 |
| | Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) | 30 |
| | Narcotics..... | 30 |
| | Alpha-Agonists | 30 |
| | Preanesthesia and Anesthesia in Dogs | 30 |
| | Chemical Restraint (Sedation) in Dogs..... | 32 |
| | Pain Recognition in Dogs..... | 33 |
| | Treatment of Pain in Dogs..... | 34 |
| | Local Anesthetics | 34 |
| | NSAIDs | 34 |
| | Narcotics..... | 34 |
| | Alpha-Agonists..... | 35 |

| | |
|--|-----------|
| Preanesthesia and Anesthesia in Cats..... | 35 |
| Chemical Restraint (Sedation) in Cats | 36 |
| Pain Recognition in Cats | 37 |
| Treatment of Pain in Cats | 37 |
| Local Anesthetics | 37 |
| NSAIDs | 37 |
| Narcotics..... | 37 |
| Alpha-Agonists..... | 38 |
| Preanesthesia and Anesthesia in Guinea Pigs | 38 |
| Chemical Restraint (Sedation) in Guinea Pigs | 38 |
| Pain Recognition in Guinea Pigs..... | 38 |
| Treatment of Pain in Guinea Pigs..... | 39 |
| Local Anesthetic Agents..... | 39 |
| NSAIDs | 39 |
| Narcotics..... | 39 |
| Alpha-Agonists..... | 39 |
| Preanesthesia and Anesthesia in Pigs..... | 39 |
| Chemical Restraint (Sedation) in Pigs | 41 |
| Pain Recognition in Pigs | 41 |
| Treatment of Pain in Pigs | 41 |
| Local Anesthetic Agents..... | 41 |
| NSAIDs | 42 |
| Narcotics..... | 42 |
| Alpha-Agonists..... | 42 |
| Preanesthesia and Anesthesia in Calves, Sheep, and Goats..... | 42 |
| Chemical Restraint (Sedation) in Small Ruminants..... | 43 |
| Recognition of Pain in Small Ruminants | 43 |
| Treatment of Pain in Small Ruminants | 44 |
| Local Anesthetic Agents..... | 44 |
| NSAIDs | 44 |
| Narcotics..... | 44 |
| Alpha-Agonists..... | 44 |
| Preanesthesia and Anesthesia in Rhesus Monkeys | 45 |
| Chemical Restraint (Sedation) in Rhesus Monkeys | 45 |
| Pain Recognition in Rhesus Monkeys..... | 45 |
| Treatment of Pain in Rhesus Monkeys..... | 46 |
| Local Anesthetics | 46 |
| NSAIDs | 46 |
| Narcotics..... | 46 |
| Conclusions | 47 |
| 3 Normal Cardiac Function Parameters..... | 55 |

| | |
|---|-----------|
| 4 Measuring Cardiac Function | 65 |
| The Pressure–Volume Relationship..... | 67 |
| Another Measure of Ventricular Elasticity | 68 |
| Measurement of Electrical Activity | 68 |
| Measurement of Pressure | 69 |
| Echocardiography..... | 70 |
| History | 70 |
| Physics of Echo Technology..... | 72 |
| Doppler Flow Velocity and Tissue Doppler Imaging..... | 74 |
| History | 74 |
| Physics of Doppler Technology..... | 75 |
| Tissue Doppler Imaging | 76 |
| Examples of Ultrasound Data Reported Using | |
| <20-MHz Transducers..... | 77 |
| Examples of Ultrasound Data Reported Using 20-MHz | |
| (or Greater) Transducers..... | 78 |
| Summary of Information Needed to Ascertain | |
| the Reliability of Ultrasound Data..... | 80 |
| Techniques for Measuring Ventricular Volumes | 80 |
| Radiographic..... | 80 |
| Echocardiography and Tissue Doppler Imaging | 81 |
| Sonomicrometry | 81 |
| Radionuclide Ventriculography..... | 81 |
| Magnetic Resonance Imaging and Computer-Assisted | |
| Tomography Scan..... | 82 |
| Conductance-Derived Volume Measurements | 82 |
| Other Measures of Myocardial Physical Properties..... | 84 |
| Myocardial Resistivity..... | 85 |
| Tissue Characterization | 85 |
| Measuring Diastolic Dysfunction..... | 86 |
| 5 Measuring Vascular Function and Ventricular/ | |
| Arterial Coupling Dynamics | 93 |
| History..... | 93 |
| Quantification of Arterial Compliance | 94 |
| Force-Displacement Measurements | 95 |
| Pulse Wave Velocity | 97 |
| Modeling Techniques for Estimating Vascular Mechanical Behavior | 99 |
| Ventricular/Vascular Coupling | 101 |
| Ventricular/Vascular Coupling Determined Using | |
| the Input Impedance | 101 |
| Ventricular/Vascular Coupling Determined Using | |
| the Ratio of Ventricular End-Systolic Pressure | |
| and Stroke Volume (P_{es}/SV) Designated E_a | 102 |

| | |
|--|------------|
| Diastolic Ventricular/Vascular Coupling | 104 |
| MRI Imaging for Detection of Ventricular/Vascular Coupling | 104 |
| Tissue Doppler Imaging and Elasticity Imaging | 104 |
| 6 Isolated Heart Preparations, Problems, and Pitfalls | 109 |
| Development of the Isolated Heart Preparation | 109 |
| Retrograde Perfusion Preparations (The Langendorff Preparation)..... | 112 |
| Choosing between the Pressure-Regulated or Flow-Regulated | |
| Langendorff-Type Preparation | 114 |
| The Isolated, Working, In Situ Heart-Lung Preparation | 114 |
| The Isolated Working Left Heart Preparation | 114 |
| The Langendorff-Type Perfused Working Left Heart Preparation..... | 115 |
| The Biventricular Isolated Working Heart Preparation..... | 117 |
| The Biventricular, Retrograde-Perfused, Working Heart Preparation..... | 119 |
| Perfusion Solutions | 120 |
| Support Animals..... | 122 |
| Washed Red Blood Cell Addition to the Perfusate | 122 |
| Problems and Pitfalls..... | 123 |
| Exclusion Criteria..... | 123 |
| Problems Common to Crystalloid Perfusion..... | 124 |
| Contamination | 124 |
| Temperature | 125 |
| Metabolic “Poisoning” | 125 |
| Pacing vs. Spontaneously Beating Preparations..... | 125 |
| Frequency Response Testing of Ventricular Pressure | |
| Recording Systems | 126 |
| Heterotopic Transplants..... | 126 |
| 7 Cardiovascular Effects of Anesthetics, Sedatives, Postoperative Analgesic Agents, and Other Pharmaceuticals | 131 |
| Barbiturates | 131 |
| Propofol..... | 132 |
| α -Chloralose..... | 133 |
| Urethane | 134 |
| α -Chloralose + Urethane..... | 134 |
| Steroid Anesthetic Agents..... | 134 |
| Inhalation Anesthetic Agents | 135 |
| General | 135 |
| Halothane..... | 136 |
| Isoflurane | 137 |
| Desflurane..... | 138 |
| Sevoflurane | 139 |
| Ether | 140 |
| Nitrous Oxide | 140 |

| | |
|---|-----|
| Trichloroethylene..... | 140 |
| The Opioids | 141 |
| Morphine | 141 |
| Meperidine (Demerol) | 144 |
| Methadone | 144 |
| Levomethadone..... | 145 |
| Pentazocine..... | 145 |
| Fentanyl | 145 |
| Butorphanol | 147 |
| Buprenorphine | 147 |
| Oxymorphone | 148 |
| Naloxone..... | 148 |
| Other Synthetic Opioids | 149 |
| Dissociative Anesthetic Agents..... | 150 |
| Ketamine..... | 150 |
| Tiletamine..... | 151 |
| Imidazole and Other Hypnotic, Amnesiac, Anxiolytic, or Antipsychotic Compounds..... | 152 |
| Etomidate..... | 152 |
| Metomidate..... | 153 |
| Benzodiazepines | 153 |
| Rilmenidine | 155 |
| α -2 Adrenergic Receptor Agonists..... | 156 |
| Medetomidine and Dexmedetomidine..... | 156 |
| Clonidine | 157 |
| β -2-Adrenergic Receptor Agonists | 157 |
| Clenbuterol | 157 |
| KUR-1246 | 158 |
| Fenoterol..... | 158 |
| Rauwolfia Derivatives | 158 |
| Reserpine | 158 |
| Phenothiazine Derivatives | 160 |
| Chlorpromazine and Promazine | 160 |
| Acetylpromazine (Acepromazine)..... | 162 |
| Other Phenothiazine Derivatives | 163 |
| Triflupromazine, Levomepromazine, Prochlorperazine (thioridazine), Cyamemazine | 163 |
| Butyrophenones..... | 164 |
| Droperidol..... | 164 |
| Haloperidol..... | 165 |
| Azaperone..... | 166 |
| Other Antipsychotic/Anxiolytic/Antidepressant (Tranquilizer) Drugs..... | 166 |
| Tricyclic Antidepressants | 167 |
| Selective Serotonin Uptake Inhibitors | 167 |

| | |
|--|-----|
| Atypical Antipsychotics | 169 |
| Sertindole..... | 169 |
| Pimozide | 169 |
| Clozapine | 169 |
| Risperidone..... | 170 |
| Amisulpride | 170 |
| Minaprine | 171 |
| Atypical Antipsychotics | 171 |
| Aripiprazole | 171 |
| Fezolamine | 171 |
| Olanzapine | 171 |
| Lortalamine..... | 171 |
| Xylazine..... | 172 |
| Drugs in Combination Providing Neurolept Analgesia/Anesthesia..... | 172 |
| Metomidate + Azaperone | 172 |
| Medetomidine + Butorphanol..... | 173 |
| Medetomidine + Butorphanol + Midazolam | 173 |
| Medetomidine + Buprenorphine + Ketamine..... | 173 |
| Medetomidine + Midazolam | 174 |
| Medetomidine + Hydromorphone | 174 |
| Dexmedetomidine + Butorphanol | 174 |
| Medetomidine + Ketamine | 174 |
| Medetomidine + Ketamine + Midazolam..... | 175 |
| Dexmedetomidine + Ketamine | 175 |
| Ketamine in Combination with Tranquilizers | 175 |
| Ketamine + Acepromazine | 175 |
| Ketamine + Xylazine | 176 |
| Ketamine + Xylazine + Guaifenesin | 178 |
| Ketamine + Xylazine + Buprenorphine..... | 178 |
| Ketamine + Diazepam | 178 |
| Midazolam + Butorphanol..... | 179 |
| Midazolam + Fentanyl + Fluanisone | 179 |
| Midazolam + Methadone + Propofol + Isoflurane + Continuous | |
| Infusion of Propofol and Fentanyl..... | 179 |
| Acepromazine + Meperidine | 179 |
| Fentanyl + Droperidol (Innovar-Vet®)..... | 180 |
| Azaperone + Metomidate | 180 |
| Acepromazine + Etorphine..... | 180 |
| Fentanyl + Morphine | 180 |
| Fentanyl + Propofol | 181 |
| Xylazine + Morphine..... | 181 |
| Oxymorphone + Bupivacaine | 181 |
| Tiletamine + Zolazepam (Telazol®, Zoletil®)..... | 181 |
| Local Anesthetic Agents | 182 |
| Non-steroidal Anti-inflammatory Agents..... | 183 |

| | |
|---|------------|
| Neuromuscular Blocking Agents | 185 |
| Aminoglycoside, Fluoroquinolone, and Anthracycline | |
| Antibiotics | 187 |
| 8 Naturally Occurring and Iatrogenic Animal Models of Valvular, Infectious, and Arrhythmic Cardiovascular Disease..... | 203 |
| Congenital Cardiac Defects, General Information | 203 |
| Genetically Engineered Models, General Information..... | 204 |
| Naturally Occurring Models of Valvular Disease | 205 |
| Iatrogenic Models of Valvular Disease | 207 |
| Infectious Cardiovascular Disease | 208 |
| Bartonella sp..... | 208 |
| Borrelia sp | 208 |
| Coxsackievirus sp..... | 209 |
| Diphtheritic Myocarditis | 209 |
| Encephalomyocarditis Virus..... | 210 |
| Autoimmune Myocarditis | 210 |
| Infectious Complications Following Burn Injury..... | 210 |
| Arrhythmic Cardiovascular Disease..... | 211 |
| Naturally Occurring Cardiac Arrhythmias | 211 |
| Iatrogenic Cardiac Arrhythmias | 211 |
| 9 Iatrogenic Models of Ischemic Heart Disease..... | 219 |
| Global Ischemia | 219 |
| Regional Ischemia..... | 221 |
| 10 Iatrogenic, Transgenic, and Naturally Occurring Models of Cardiomyopathy and Heart Failure | 231 |
| Naturally Occurring Models of Cardiomyopathy | 232 |
| Heritable HCM in Cats | 232 |
| DCM in Dogs | 233 |
| Cattle with Cardiomyopathy and Woolly Hair | |
| Coat Syndrome..... | 234 |
| Primates..... | 235 |
| Whales..... | 235 |
| Iatrogenic Models of Cardiomyopathy and Heart Failure | 235 |
| Ventricular Arrhythmia | 235 |
| Increasing the Ventricular Workload..... | 236 |
| Rapid Cardiac Pacing..... | 236 |
| Pressure Overload | 236 |
| Volume Overload | 237 |
| Valvular Stenoses or Insufficiencies | 237 |

| | |
|---|------------|
| Other Iatrogenic Models of Cardiomyopathy and Heart Failure | 237 |
| Anthracycline-Induced Cardiomyopathy | 237 |
| Diabetic and Lipid-Toxic Models of Cardiomyopathy | 238 |
| Chronic Myocardial Ischemia Models of Cardiomyopathy | 238 |
| Toxicosis and Mineral-Deficient Models of Cardiomyopathy | 239 |
| Autoimmune Models of Cardiomyopathy | 239 |
| Hyperthyroid and Hyper-Adrenergic Models of Cardiomyopathy | 240 |
| Chronic Hypoxia Models of Cardiomyopathy | 240 |
| Liver Cirrhosis Models of Cardiomyopathy | 240 |
| Murine Cysticercosis Model of Cardiomyopathy | 240 |
| Commercially Available Inbred-Rat Models of Cardiomyopathy and Heart Failure | 240 |
| Transgenic Models of Cardiomyopathy and Heart Failure | 241 |
| Mouse and Rat Models of Familial Hypertrophic Cardiomyopathy and HCM | 241 |
| Mouse and Rat Models of DCM | 242 |
| Overexpression Models | 245 |
| 11 Iatrogenic, Congenic, and Transgenic Models of Hypertension | 259 |
| Renovascular Hypertension | 260 |
| 2K1C and 1K1C Renovascular Hypertension in Rats | 261 |
| 2K1C and 1K1C Renovascular Hypertension Models in Mice | 263 |
| Renovascular Hypertension Models in Rabbits | 264 |
| 1K1C Renovascular Hypertension in Dogs | 265 |
| Renovascular Hypertension in Pigs | 265 |
| Genetic Models of Hypertension | 266 |
| Spontaneously Hypertensive Rat | 266 |
| Stroke-Prone SHR | 269 |
| Dahl Salt-Sensitive and Insensitive Rats | 270 |
| Other Salt-Sensitive (Salt-Induced) Models of Hypertension | 272 |
| Angiotensin-II-Induced Hypertension | 273 |
| DOCA-Induced Hypertension | 276 |
| NO-Synthesis Blockade Hypertension | 278 |
| Glucocorticoid-Induced Hypertension | 280 |
| Intrauterine Growth-Restricted Induced Hypertension | 281 |
| Other Transgenic and Congenic Models of Hypertension | 283 |
| The mRen-2 Model | 283 |
| ATR-1 Models | 283 |
| Angio-II Overexpression Models | 284 |
| G-Protein Models | 284 |
| eNOS Models | 285 |
| Endothelin Models | 285 |
| Chromogranin-A Models | 286 |
| PPAR- α Models | 286 |

| | |
|--|------------|
| Bradykinin-2 Models | 286 |
| Estrogen Models | 287 |
| Corin Models | 287 |
| Vitamin D Receptor Models | 287 |
| Glucocorticoid Receptor Models | 287 |
| Smoothelin Models | 288 |
| Adiponectin Models | 288 |
| Aryl Hydrocarbon Models | 288 |
| Parathyroid Hormone Type 1 Receptor Models..... | 289 |
| Profilin Models..... | 289 |
| Oligodeoxynucleotide Models | 289 |
| Multiple Transgenic Models | 290 |
| Congenetic Models | 290 |
| Other Models of Systemic Hypertension | 291 |
| Pulmonary Hypertension | 292 |
| Hypoxia-Induced Pulmonary Hypertension | 292 |
| Monocrotaline-Induced Pulmonary Hypertension..... | 293 |
| Transgenic Models of Pulmonary Hypertension | 294 |
| 12 Naturally Occurring, Iatrogenic and Transgenic Models of Atherosclerotic Disease | 307 |
| Characteristics of Plaque Rupture and Resulting Thrombosis | 309 |
| Implication of New “Players” in the Pathogenesis of Atherosclerotic Disease | 309 |
| Animal Models..... | 310 |
| Naturally Occurring Animal Models of Atherosclerosis | 311 |
| Primate Models of Atherosclerosis..... | 311 |
| Swine Models of Atherosclerosis | 312 |
| Dog and Cat Models | 312 |
| Rabbit Models..... | 313 |
| Transgenic Rabbit Models | 314 |
| Rat Models | 315 |
| Transgenic Rat Models | 317 |
| Mouse Models..... | 317 |
| Mice Models of Glucose Intolerance | 317 |
| Graft Vasculopathy..... | 323 |
| Hamsters | 324 |
| Sand Rats | 324 |
| 13 Animal Models for the Study of Neurohumeral and Central Neural Control of the Cardiovascular System..... | 331 |
| The Autonomic Nervous System in Blood Pressure | |
| Homeostasis and Cardiorespiratory Reflex Responses..... | 333 |
| Rostal and Caudal Ventrolateral Medulla | 334 |

| | |
|---|------------|
| Nucleus Tractus Solitarius | 337 |
| Hypothalamic Paraventricular Nucleus..... | 339 |
| Periaqueductal Gray | 340 |
| Anterior and Posterior Hypothalamic Areas..... | 342 |
| Median Preoptic Nucleus..... | 342 |
| Nucleus Cuneatus..... | 342 |
| Lateral Parabrachial Nucleus and the Dorsal Raphe Nucleus..... | 343 |
| Caudal Vestibular Nucleus | 343 |
| Gender Effects on Central Control of Cardiovascular Responses | 343 |
| Neurohumeral Control | 344 |
| Renin-Angiotensin System | 344 |
| Serotonin | 344 |
| Vasopressin | 345 |
| Endogenous Ouabain-Like Substance | 345 |
| Opioids..... | 345 |
| Tyrosine Hydroxylase and Phenylethanolamine | |
| N-Methyltransferase..... | 346 |
| Neuropeptide Y | 346 |
| Leptin | 346 |
| Dopamine- β -Hydroxylase..... | 346 |
| 11- β -Hydroxylase and Aldosterone Synthase | 347 |
| Orexin | 347 |
| Urotensin-II..... | 347 |
| Cholecystokinin | 348 |
| 14 Other Transgenic Animal Models Used | |
| in Cardiovascular Studies | 355 |
| Sex-Related Responses | 356 |
| Kinases | 357 |
| Oxidases and Oxygenases..... | 358 |
| Adenosine and Adrenergic Receptors..... | 359 |
| Nitric Oxide Synthase | 360 |
| Metabolic Syndrome..... | 361 |
| Xenotransplantation | 362 |
| Na ⁺ /Ca ²⁺ and Na ⁺ /H ⁺ Exchangers..... | 364 |
| Inflammatory Cytokines..... | 365 |
| Peroxisome Proliferator-Activated Receptor | 366 |
| Renin-Angiotensin System | 366 |
| Bradykinin-2 Receptor..... | 367 |
| Apolipoprotein-E and Low-Density Lipoprotein | |
| Knockout Models..... | 367 |
| Toll-Like Receptors..... | 368 |
| Caveolin-1 (Cav-1)..... | 368 |
| Long QT Syndrome | 369 |

| | |
|--|------------|
| Nuclear Factor Kappa-B | 369 |
| Orphan Nuclear Receptors | 370 |
| Troponin | 370 |
| Chromogranin A | 371 |
| Lectin-Like Oxidized Low-Density Lipoprotein Receptor | 371 |
| Junctin | 371 |
| Connexin | 372 |
| Phospholamban | 372 |
| Fas Ligand | 373 |
| Proteases, Metalloproteinases, and ATPases | 373 |
| Binary Calsequestrin/P2Xr-Purinergic Receptor (CSQ/P2X4R) Transgenics | 374 |
| pro-ANP Gene Disrupted Mouse | 375 |
| Macrophage Colony-Stimulating Factor | 375 |
| Endothelin-1 | 375 |
| Elastin | 376 |
| α -2-Antiplasmin | 376 |
| cAMP Response Element Binding Protein | 376 |
| Fatty Acid Transport Protein: CD36 | 376 |
| Clotting Factor XIII | 377 |
| Apelin | 377 |
| T-Box Transcription Factor | 377 |
| Thrombospondin-1 and Its Receptor CD47 | 377 |
| Polyomavirus Middle T Antigen | 378 |
| Thrombopoietin Receptor | 378 |
| Vascular Endothelial Growth Factor | 378 |
| Osteopontin | 378 |
| ATP-Binding Membrane Cassette Transporter-A1 | 379 |
| The K ⁺ /Cl ⁻ Cotransporter KCC3 | 379 |
| Aldosterone Synthase Overexpression | 379 |
| Cysteine and Glycine-Rich Protein-2 (CSRP-2) | 379 |
| Parathyroid Hormone Type-1 Receptor and PTH/PTH-Related Protein | 380 |
| Vitamin D Receptor | 380 |
| Thromboxane Receptor (Tp) | 380 |
| T and B Cells | 380 |
| Vanilloid Type-1 Receptors (TRPV-1) | 381 |
| Serotonin Transporter (SERT) | 381 |
| CC Chemokine Receptor-2 (CCR-2) | 381 |
| Thymosin β -4 | 381 |
| Index | 393 |



<http://www.springer.com/978-0-387-95961-0>

Animal Models in Cardiovascular Research

Gross, D.

2009, XXVI, 431 p., Hardcover

ISBN: 978-0-387-95961-0